BriaCell Therapeutics Corp. is an immuno-oncology company that is developing a more targeted and less toxic approach to managing cancer. Utilizing its fully owned BriaVax, the company has demonstrated unique and unprecedented results in 18 patients spanning two Phase 1 FDA clinical trials. Most uniquely, BriaCell has achieved these results in patients who had prior failed all standard available therapies including various kinds of chemotherapy. In some cases, the lifespan was three to five times longer than expected. The results produced little to no side effects, with regression occurring within six weeks. The company will soon begin a Phase 1/2a trial in order to test up to 24 more late-stage cancer patients.